Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to evaluate the efficacy and safety of combining fenofibrate and simvastatin in patients with mixed hyperlipidemia at risk of cardiovascular diseases.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
1,040
Combination of Fenofibrate 145mg and Simvastatin 20mg
Combination of Fenofibrate and Simvastatin 40 mg
Simvastatin 40 mg
Percent change from baseline to 24 weeks of treatment in Triglycerides
Time frame: 12 weeks
Percent change from baseline to 24 weeks of treatment in HDL-C
Time frame: 12 weeks
Percent change from baseline to 24 weeks of treatment in LDL-C
Time frame: 12 weeks
Percent change from baseline to 24 weeks of treatment in Triglycerides
Time frame: 24 weeks
Percent change from baseline to 24 weeks of treatment in HDL-C
Time frame: 24 weeks
Percent change from baseline to 24 weeks of treatment in LDL-C
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site 008
Brno, Czechia
Site 009
Brno, Czechia
Site 010
Brno, Czechia
Site 015
Hradisk, Czechia
Site 019
Karlovy Vary, Czechia
Site 014
Kladno, Czechia
Site 005
Nymburk, Czechia
Site 012
Olomouc, Czechia
Site 013
Olomouc, Czechia
Site 007
Pilsen, Czechia
...and 100 more locations